Table 1 Baseline characteristics of the 432 pregnant women who participated in the PACOME trial
Category | Subcategory | N (%) or mean (SD)* |
|---|---|---|
Sociodemographic characteristics | ||
Health centre | CNHU | 136 (31.5) |
HIA | 76 (17.6) | |
CLP | 29 (6.7) | |
HZ de Suru Léré | 146 (33.8) | |
HOMEL | 45 (10.4) | |
Age (years) (N = 431) | 29.2 (4.7) | |
Education | None or unknown | 117 (27.1) |
Primary | 153 (35.3) | |
Secondary | 128 (29.8) | |
University | 34 (7.8) | |
Marital status | Single | 25 (5.8) |
Married (monogam) | 272 (63.0) | |
Married (polygam) | 131 (30.2) | |
Other or unknown | 4 (1.0) | |
General and obstetric characteristics | ||
Obesity (BMI ≥30 kg/m2) (N = 427) | 52 (12.2) | |
Sickle cell trait (N = 267) | Homozygote (SS) | 16 (6.0) |
Heterozygote (AS) | 26 (9.7) | |
Primigravid | 50 (11.6) | |
Number of live born | 1.7 (1.5) | |
Gestational age at inclusion (weeks) | 21.7 (3.8) | |
Symptomatic malaria in early pregnancy before inclusion (N = 424) | 45 (10.6) | |
HIV–related characteristics | ||
Time since HIV diagnosis (months)* | 15 (1–42)* | |
WHO staging | 1 | 303 (70.1) |
2 | 62 (14.4) | |
3 | 65 (15.1) | |
4 | 2 (0.5) | |
CD4 cell count (/mm3)* | 342 (230–491)* | |
Undetectable viral load (N = 257) | 82 (31.9) | |
Cotrimoxazole started before the ongoing pregnancy (N = 430) | 204 (47.4) | |
Antiretroviral therapy started before inclusion (N = 429) | 222 (51.8%) |